Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page
- Check5 days agoChange DetectedThe page’s revision/version indicator in the footer has been updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the study record details.SummaryDifference0.0%

- Check12 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedThe page metadata now shows Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check48 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check77 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior government funding operating-status notice (and Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check84 days agoChange DetectedNew site-wide notice about government funding and NIH Clinical Center status appears, and the page revision is updated to v3.4.1; core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.